W. Li

机构：Ningbo University, University of Science and Technology of China, Ministry of Education of the People's Republic of China, Southwest University, China Pharmaceutical University, Northwestern Polytechnical University, Xuzhou Medical College, Capital Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Trinity College, University of Cambridge, Southern University of Science and Technology, Beijing Geriatric Hospital, Affiliated Hospital of Xuzhou Medical College, Anhui Provincial Hospital, Guangdong Academy of Medical Sciences, Nanjing Medical University · ORCID：0009-0001-3036-0221

发表论文 94 篇 · 总被引 2411 次 · h-index 14

代表论文

• Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study (2024 · Signal Transduction and Targeted Therapy · 被引 36)
• Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma (2025 · Blood · 被引 20)
• Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects (2024 · Critical Reviews in Oncology/Hematology · 被引 17)
• Nitrogen Deprivation Drives Red Motile Cell Formation in Haematococcus pluvialis: Physiological and Transcriptomic Insights (2025 · Metabolites · 被引 5)
• Treatment outcomes of endoscopic resection for nonampullary duodenal neuroendocrine tumors (2024 · Journal of Gastrointestinal Oncology · 被引 5)
• Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death (2024 · Blood Advances · 被引 5)